At Long Last, Medications for Multiple Sclerosis

Jody Corey-Bloom, M.D., Ph.D. University of California, San Diego

Comments

At long Last, Medications for Multiplle Sclerosis
Irwin Mortman

9/5/2012 1:46:50 PM

 What is missing in this article is the efficacy rate, long term effects and cost. For example te efficacy rates forr Betaseron, Avonex, and Copaxone is about 35-40 percent and cost about $1000 per month. Furthermore, it appears several drugs are FDA approved and then we learn that consequence of their is use is fear from satisfactory, We need to stress that there are other alternatives thist MS drugs. Finally, the MS population for primary progressive MS is about 15 percent and 85 percent for relapsinig-remitting MS.

At Long Last, Medications for Multiple Sclerosis - Dana Foundation
Laura Kennedy-Hamberg

8/26/2012 3:37:21 PM

 It saddens me to see this article and truly feel it is politically motivated. Have received 12 emails in last 2 months regarding Multiple Sclerosis medications and there effects.....one is as follows.... the most widely prescribed drug for treating multiple sclerosis, interferon beta, has little or no effect on a patient’s progression to disability. The study collected data on 868 M.S. patients treated with interferon beta, comparing them with 1,788 patients who never took the drug. They found that those who took interferon beta were no less likely to suffer long-term disability than those who took none. The study was conducted by researchers at the University of British Columbia. http://www.healthaim.com/study-finds-that-multiple-sclerosis-drug-doesnt-prevent-onset-of-disability/